Drug intelligence / Profile preview

magaldrate + simethicone + oxetacaine

Development stage
Unknown
Lead developer
Alde Medi Impex
Modality
Small Molecules
Administration
Oral
01

Overview

Almag Gel is an oral antacid suspension developed by Alde Medi Impex. It is a fixed-dose combination of magaldrate (an antacid), simethicone (an anti-foaming agent), and oxetacaine (a local anesthetic). Magaldrate works by neutralizing excess stomach acid, thereby relieving heartburn and indigestion. Simethicone reduces the surface tension of gas bubbles in the gastrointestinal tract, facilitating their coalescence and passage to alleviate bloating and flatulence. Oxetacaine acts as a potent local anesthetic that remains stable in acidic environments, providing rapid and localized pain relief to the irritated or ulcerated mucosal lining of the stomach and esophagus. Almag Gel is approved and indicated for the management of hyperacidity, heartburn, bloating, gastritis, and discomfort associated with peptic ulcers.

Brand names
Almag Gel
Other names
magaldrate + simethicone + oxetacainemagaldrate + simethicone + oxethazainemagaldrate, simethicone and oxetacaine oral suspension
02

Targets

SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)SCN11A (NaV1.9)NaV alpha (Voltage-gated sodium channel alpha subunit family)

Beyond the preview

Go deeper on magaldrate + simethicone + oxetacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on magaldrate + simethicone + oxetacaine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call